Language:

Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

bioRxiv, 2022-02

2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;DOI: 10.1101/2022.02.07.479468

Digital Resources/Online E-Resources

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice
Author: Walls, Alexandra C ; Vanblargan, Laura A ; Wu, Kai ; Choi, Angela ; Navarro, Mary Jane ; Lee, Diana ; Avena, Laura ; Daniela Montes Berrueta ; Pham, Minh N ; Elbashir, Sayda ; Miranda, Marcos C ; Kepl, Elizabeth ; Johnson, Max ; Blackstone, Alyssa ; Sprouse, Kaitlin R ; Fiala, Brooke ; O'connor, Megan Ashley ; Brunette, Natalie ; Arunachalam, Prabhu S ; Shirreff, Lisa ; Rogers, Kenneth A ; Carter, Lauren ; Deborah Heydenburg Fuller ; Villinger, Francois J ; Bali Pulendran ; Diamond, Michael S ; Edwards, Darin K ; King, Neil P ; Veesler, David
Subjects: Animal models ; Antibodies ; Biotechnology ; Coronaviruses ; Patent applications ; Public health ; Severe acute respiratory syndrome coronavirus 2 ; Vaccines
Is Part Of: bioRxiv, 2022-02
Description: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development of a large number of vaccines, several of which are now approved for use in humans. Understanding vaccine-elicited antibody responses against emerging SARS-CoV-2 variants of concern (VOC) in real time is key to inform public health policies. Serum neutralizing antibody titers are the current best correlate of protection from SARS-CoV-2 challenge in non-human primates and a key metric to understand immune evasion of VOC. We report that vaccinated BALB/c mice do not recapitulate faithfully the breadth and potency of neutralizing antibody responses against VOC, as compared to non-human primates or humans, suggesting caution should be exercised when interpreting data for this animal model. Competing Interest Statement A.C.W., N.P.K., and D.V. are named as inventors on patent applications filed by the University of Washington based on the RBD-NP presented in this paper. N.P.K. is a co-founder, shareholder, paid consultant, and chair of the scientific advisory board of Icosavax, Inc. and the King lab has received an unrelated sponsored research agreement from Pfizer. D.V. has received an unrelated sponsored research agreement from Vir Biotechnology, Inc. M.S.D. is a consultant for Inbios, Vir Biotechnology, and Carnival Corporation, and on the Scientific Advisory Boards of Moderna and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Kaleido, and Emergent BioSolutions and past support from Moderna not related to these studies. K.W., A.C., and D.K.E are employees of Moderna and hold stock/stock options in the company. D.H.F. has equity interest in HDT Bio.
Publisher: Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Language: English
Identifier: DOI: 10.1101/2022.02.07.479468
Source: Coronavirus Research Database

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;DOI: 10.1101/2022.02.07.479468

Searching Remote Databases, Please Wait